Before the approval of immune checkpoint inhibitors (CPIs), the primary treatment for advanced RCC involved the use of tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor (VEGF) or molecular inhibitors targeting the mammalian target of rapamycin (mTOR). This evidence concerns the gene MTOR and renal cell carcinoma.